We can’t show the full text here under this license. Use the link below to read it at the source.
S-ketamine relieves neuropathic pain by inhibiting microglia phagocytosis of the perineuronal nets
S-ketamine reduces nerve pain by stopping immune cells from breaking down protective nerve structures
AI simplified
Abstract
C57BL/6 mice with neuropathic pain showed increased microglial activity linked to the degradation of the perineurial network (PNN).
- Neuropathic pain in mice may be connected to heightened activity that degrades PNN.
- Minocycline treatment could reduce microglial activity and improve pain thresholds.
- S-ketamine treatment may enhance pain relief by inhibiting microglial degradation of PNN.
- The interaction between microglia and PNN may play a key role in the development of neuropathic pain.
- Microglia-PNN overlap was assessed through 3D reconstruction to measure their spatial relationship.
AI simplified
Key numbers
10 mg/kg
Pain Threshold Improvement
S-ketamine dosage that effectively reduced pain behavior.
50 mg/kg
Microglial Activation Reduction
Dosage of minocycline that effectively reduced microglial activity.